Qilu Pharmaceutical
Tracked across 5 events · 30 articles · First seen Jul 13, 2026 · Last active Sep 10, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Qilu is the developer and supplier of QL2107, leveraging its R&D and manufacturing strengths to gain US market access through Cipla.
Sep 03, 2026 · 6 articles
Business
Impact: Collaboration partner; contributes to Insilico's revenue growth, but no direct impact from index inclusion.
Jul 20, 2026 · 6 articles
Business
Impact: Qilu Pharmaceutical is mentioned as a prior collaborator with Insilico, but is not directly involved in this event.
Jul 13, 2026 · 6 articles
Regulatory
Impact: Qilu Pharmaceutical is a strategic partner of ArkBio, potentially involved in manufacturing or commercialization in China.
Jul 20, 2026 · 6 articles
Tech
Insilico Medicine announced on September 9-10, 2026 that it has dosed the first patient with Rentosertib (ISM001-055 / INS018_055) in GENESIS-IPF-3, a Phase III clinical trial for idiopathic pulmonary fibrosis (IPF), at United Medical College…
Impact: Qilu Pharmaceutical is mentioned as a partner in Insilico's collaborations. The event has minimal direct impact on Qilu Pharmaceutical.
Sep 10, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Qilu Pharmaceutical live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard